Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1991 1
1992 1
1993 1
1994 6
1995 5
1996 12
1997 13
1998 12
1999 13
2000 6
2001 8
2002 17
2003 16
2004 13
2005 28
2006 21
2007 18
2008 16
2009 13
2010 22
2011 22
2012 28
2013 21
2014 20
2015 16
2016 23
2017 12
2018 17
2019 20
2020 22
2021 19
2022 17
2023 17
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

444 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Side effects of bicalutamide"
Page 1
Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial.
Tree A, Griffin C, Syndikus I, Birtle A, Choudhury A, Graham J, Ferguson C, Khoo V, Malik Z, O'Sullivan J, Panades M, Parker C, Rimmer Y, Scrase C, Staffurth J, Dearnaley D, Hall E; CHHiP investigators. Tree A, et al. Int J Radiat Oncol Biol Phys. 2022 Jun 1;113(2):305-315. doi: 10.1016/j.ijrobp.2021.12.160. Epub 2022 Jan 10. Int J Radiat Oncol Biol Phys. 2022. PMID: 35017008 Free PMC article.
Of all participants, 97% of them had concurrent short-course hormone therapy (HT), either luteinizing hormone-releasing hormone analog (LHRHa) or 150 mg of bicalutamide daily. This exploratory analysis compares efficacy and side effects in a nonrandomized com …
Of all participants, 97% of them had concurrent short-course hormone therapy (HT), either luteinizing hormone-releasing hormone analog (LHRH …
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG. Shipley WU, et al. N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529. N Engl J Med. 2017. PMID: 28146658 Free PMC article. Clinical Trial.
The incidence of late adverse events associated with radiation therapy was similar in the two groups. Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of those in the placebo group (P<0.001). ...
The incidence of late adverse events associated with radiation therapy was similar in the two groups. Gynecomastia was recorded in 69 …
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 …
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurre …
Endocrinological Approach to Adolescents with Gender Dysphoria: Experience of a Pediatric Endocrinology Department in a Tertiary Center in Turkey.
Karakılıç Özturan E, Öztürk AP, Baş F, Erdoğdu AB, Kaptan S, Kardelen Al AD, Poyrazoğlu Ş, Yıldız M, Direk N, Yüksel Ş, Darendeliler F. Karakılıç Özturan E, et al. J Clin Res Pediatr Endocrinol. 2023 Aug 23;15(3):276-284. doi: 10.4274/jcrpe.galenos.2023.2023-1-13. Epub 2023 Mar 29. J Clin Res Pediatr Endocrinol. 2023. PMID: 36987788 Free PMC article.
CONCLUSION: All treatments were generally well tolerated and effective, including bicalutamide, and no significant side effects were observed. Transition clinics played an important role in the better management of gender reassignment processes....
CONCLUSION: All treatments were generally well tolerated and effective, including bicalutamide, and no significant side eff …
Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know.
Carvalho RM, Santos LDN, Ramos PM, Machado CJ, Acioly P, Frattini SC, Barcaui CB, Donda ALV, Melo DF. Carvalho RM, et al. J Cosmet Dermatol. 2022 Oct;21(10):4171-4175. doi: 10.1111/jocd.14773. Epub 2022 Feb 10. J Cosmet Dermatol. 2022. PMID: 35032336 Review.
This review aimed to summarize and discuss the key information on this new therapy for FPHL. Bicalutamide has no diuretic effect. It does not cross the blood-brain barrier, and it has little effect on serum luteinizing hormone. Additionally, bicalutamide was found t …
This review aimed to summarize and discuss the key information on this new therapy for FPHL. Bicalutamide has no diuretic effect. It …
ARN-509: a novel antiandrogen for prostate cancer treatment.
Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH. Clegg NJ, et al. Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20. Cancer Res. 2012. PMID: 22266222 Free PMC article.
While established and novel AR pathway-targeting agents display clinical efficacy in metastatic CRPC, dose-limiting side effects remain problematic for all current agents. In this study, we report the discovery and development of ARN-509, a competitive AR inhibitor …
While established and novel AR pathway-targeting agents display clinical efficacy in metastatic CRPC, dose-limiting side effects …
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Gu W, et al. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075260 Clinical Trial.
The most common grade 3 or worse adverse events of any cause in the safety population were hypertension (26 [8%] of 323 patients in the rezvilutamide group vs 24 [7%] of 324 patients in the bicalutamide group), hypertriglyceridaemia (24 [7%] vs seven [2%]), increase …
The most common grade 3 or worse adverse events of any cause in the safety population were hypertension (26 [8%] of 323 patients in t …
Mechanism of non-steroidal anti-androgen-induced liver injury: Reactive metabolites of flutamide and bicalutamide activate inflammasomes.
Kato R, Yamada T, Noda T, Tanaka S, Kohda Y, Ijiri Y. Kato R, et al. Toxicol In Vitro. 2023 Aug;90:105606. doi: 10.1016/j.tiv.2023.105606. Epub 2023 May 3. Toxicol In Vitro. 2023. PMID: 37146920
Flutamide is a non-steroidal anti-androgen agent, which is mainly used for the treatment of prostate cancer. Flutamide is known to cause severe adverse events, which includes idiosyncratic liver injury. However, details of the mechanism of these adverse reactions ha …
Flutamide is a non-steroidal anti-androgen agent, which is mainly used for the treatment of prostate cancer. Flutamide is known to cause sev …
An evaluation of bicalutamide in the treatment of prostate cancer.
Schellhammer PF, Davis JW. Schellhammer PF, et al. Clin Prostate Cancer. 2004 Mar;2(4):213-9. doi: 10.3816/cgc.2004.n.002. Clin Prostate Cancer. 2004. PMID: 15072604 Review.
Current therapies for prostate cancer often include medical or surgical castration, which cause adverse effects on physical and sexual function; therefore, greater attention has been focused on quality of life. ...Current evidence demonstrates that bicalutamide …
Current therapies for prostate cancer often include medical or surgical castration, which cause adverse effects on physical an …
Treatment of bicalutamide-induced breast events.
Sieber PR. Sieber PR. Expert Rev Anticancer Ther. 2007 Dec;7(12):1773-9. doi: 10.1586/14737140.7.12.1773. Expert Rev Anticancer Ther. 2007. PMID: 18062751 Review.
Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. ...The ongoing bicalutamide Early Prostate Cancer (EPC) program has shown that breast events, defined as gynecomastia, breast pain or both, are a significant limitation of bicalutamide. …
Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. ...The ongoing bicalutamide Early Prostate Cancer (EP …
444 results